This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NEOG Stock Gains From New Addition to the Petrifilm Product Line
by Zacks Equity Research
Neogen expands the Petrifilm product line with the introduction of Petrifilm Bacillus cereus Count Plate.
Reasons to Retain STE Stock in Your Portfolio Now
by Zacks Equity Research
STERIS' strong prospects in the healthcare business bode well for investors.
Bioproduction Prospects to Drive TMO Shares Despite Macroeconomic Woes
by Zacks Equity Research
TMO's recent strategic acquisitions, including the $3.1-billion acquisition of Olink Holdings, are likely to drive future growth.
SNN Stock Might Rise Following FDA Nod for AETOS Stemless
by Zacks Equity Research
Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty.
LH Stock May Gain From Select MAWD Pathology Asset Purchase Deal
by Zacks Equity Research
Labcorp is set to acquire select assets of MAWD Pathology Group.
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave
by Urmimala Biswas
MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar their prospects.
ZBH Stock Might Rise Following FDA Nod for OsseoFit
by Zacks Equity Research
Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Teleflex Expands CVC Portfolio in EMEA With New Launch: Stock to Gain?
by Zacks Equity Research
Teleflex introduces the Arrowg+ard Blue Plus MSB Procedure Kit in the EMEA.
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' robust potential in Structural heart and long-term strategy instill optimism.
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
QIAGEN Stock Gains Following the Latest Launch of IPA Interpret
by Zacks Equity Research
QGEN announces the launch of IPA Interpret to extend the analysis capabilities of a human-curated knowledge base with AI technology.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Omnicell Introduces OmniSphere Platform, Stock to Gain
by Zacks Equity Research
Omnicell introduces OmniSphere. Additionally, the company showcases a full portfolio of outcomes-centric solutions at the ASHP Midyear 2024.
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?
by Zacks Equity Research
TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay.
Reasons to Retain Envista Stock in Your Portfolio for Now
by Zacks Equity Research
NVST's Specialty Products and Technologies business' strong performance appears promising. Yet, a leveraged balance sheet is worrisome.
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues
by Zacks Equity Research
IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth.
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?
by Zacks Equity Research
Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment.
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements
by Zacks Equity Research
QGEN achieves milestone with more than 1,000 EZ2 Connect placements worldwide, contributing to a global installed base of over 5,500 EZ series instruments.
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain ZBH Stock in Your Portfolio for Now
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising.
Reasons to Retain TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.
CRL Stock to Gain From the Global Biotech Incubator Program Launch
by Zacks Equity Research
Charles River's new initiative specifically caters to early-stage biotechnology developers.
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
by Zacks Equity Research
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.